Stock RMD RESMED, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ResMed, Inc.

Equities

RMD

US7611521078

Advanced Medical Equipment & Technology

Market Closed - Nyse
Other stock markets
 16:00:02 2024-05-02 EDT 		5-day change 1st Jan Change
218.2 USD +1.46% Intraday chart for ResMed, Inc. +18.93% +26.82%
04-26 Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
04-26 Top Midday Gainers MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 17,498 27,776 35,903 30,691 32,133 32,048 - -
Enterprise Value (EV) 1 18,622 28,489 36,263 31,192 33,346 32,572 31,664 30,690
P/E ratio 43.6 x 45 x 76.1 x 39.6 x 35.9 x 31.4 x 26.5 x 24 x
Yield 1.23% 0.81% 0.63% 0.8% 0.82% 0.9% 0.99% 1.03%
Capitalization / Revenue 6.71 x 9.39 x 11.2 x 8.58 x 7.61 x 6.85 x 6.37 x 5.95 x
EV / Revenue 7.14 x 9.63 x 11.3 x 8.72 x 7.9 x 6.97 x 6.29 x 5.7 x
EV / EBITDA 23.5 x 29.5 x 33.8 x 26.8 x 25.3 x 20.7 x 18.1 x 16.3 x
EV / FCF 47.7 x 40.3 x 57.2 x 144 x 58.1 x 28.4 x 25 x 22 x
FCF Yield 2.1% 2.48% 1.75% 0.69% 1.72% 3.52% 3.99% 4.55%
Price to Book 8.43 x 11.1 x 12.4 x 9.35 x 7.76 x 6.56 x 5.49 x 4.57 x
Nbr of stocks (in thousands) 143,393 144,668 145,640 146,405 147,062 146,907 - -
Reference price 2 122.0 192.0 246.5 209.6 218.5 218.2 218.2 218.2
Announcement Date 19-07-25 20-08-05 21-08-05 22-08-11 23-08-03 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2,607 2,957 3,197 3,578 4,223 4,675 5,032 5,388
EBITDA 1 792.1 966 1,074 1,162 1,317 1,575 1,746 1,889
EBIT 1 641.3 811.2 903.7 1,000 1,224 1,466 1,633 1,782
Operating Margin 24.6% 27.43% 28.27% 27.96% 28.99% 31.35% 32.44% 33.07%
Earnings before Tax (EBT) 1 518.8 733.1 883.7 960.5 1,102 1,297 1,518 1,671
Net income 1 404.6 621.7 474.5 779.4 897.6 1,023 1,236 1,370
Net margin 15.52% 21.02% 14.84% 21.78% 21.25% 21.89% 24.55% 25.42%
EPS 2 2.800 4.270 3.240 5.300 6.090 6.941 8.221 9.107
Free Cash Flow 1 390.3 706.9 634 216.3 573.6 1,147 1,264 1,395
FCF margin 14.98% 23.91% 19.83% 6.05% 13.58% 24.52% 25.12% 25.89%
FCF Conversion (EBITDA) 49.28% 73.18% 59.01% 18.62% 43.55% 72.8% 72.4% 73.86%
FCF Conversion (Net income) 96.48% 113.71% 133.61% 27.75% 63.91% 112.05% 102.31% 101.84%
Dividend per Share 2 1.500 1.560 1.560 1.680 1.800 1.964 2.151 2.245
Announcement Date 19-07-25 20-08-05 21-08-05 22-08-11 23-08-03 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 894.9 864.5 914.7 950.3 1,034 1,117 1,122 1,102 1,163 1,197 1,215 1,169 1,234 1,268 1,305
EBITDA 1 289.5 276.6 294.7 312.8 326.4 345 333 363.7 390.5 418.1 426.6 398 430.4 451.2 464.6
EBIT 1 248.7 234.3 255.4 290.8 305.5 321.2 307 318.8 365.5 393.6 391.8 374.1 407.2 420.4 425
Operating Margin 27.79% 27.1% 27.92% 30.6% 29.55% 28.76% 27.36% 28.92% 31.43% 32.88% 32.24% 32% 33% 33.15% 32.58%
Earnings before Tax (EBT) 1 237.3 226.3 238.1 261.8 273.7 289.4 276.8 272.2 259.5 375.4 358.5 352.7 378.3 392.5 398
Net income 1 201.8 179 195.1 210.5 224.9 232.5 229.7 219.4 208.8 300.5 293.8 279.6 303.4 314.5 320
Net margin 22.55% 20.71% 21.32% 22.15% 21.76% 20.82% 20.47% 19.91% 17.96% 25.1% 24.17% 23.92% 24.59% 24.8% 24.53%
EPS 2 1.370 1.220 1.330 1.430 1.530 1.580 1.560 1.490 1.420 2.040 1.987 1.875 2.025 2.095 2.165
Dividend per Share 2 0.4200 0.4200 0.4200 0.4400 0.4400 0.4400 0.4800 0.4800 0.4800 - 0.4947 0.5202 0.5202 0.5202 0.5202
Announcement Date 22-01-27 22-04-28 22-08-11 22-10-27 23-01-26 23-04-27 23-08-03 23-10-26 24-01-24 24-04-25 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 1,124 713 360 502 1,213 524 - -
Net Cash position 1 - - - - - - 384 1,357
Leverage (Debt/EBITDA) 1.419 x 0.738 x 0.3352 x 0.4317 x 0.9211 x 0.3326 x - -
Free Cash Flow 1 390 707 634 216 574 1,147 1,264 1,395
ROE (net income / shareholders' equity) 25.5% 27.2% 29% 27.2% 25.4% 24.4% 24.4% 23.2%
ROA (Net income/ Total Assets) 14.7% 14.3% 16.8% 17.3% 16% 16.8% 18% 17.8%
Assets 1 2,756 4,348 2,831 4,500 5,598 6,088 6,874 7,684
Book Value Per Share 2 14.50 17.30 19.90 22.40 28.10 33.30 39.70 47.70
Cash Flow per Share 2 3.180 5.510 5.030 2.390 4.700 8.740 9.430 11.10
Capex 1 68.7 95.3 103 135 120 116 129 143
Capex / Sales 2.64% 3.22% 3.21% 3.77% 2.83% 2.49% 2.57% 2.65%
Announcement Date 19-07-25 20-08-05 21-08-05 22-08-11 23-08-03 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ResMed, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
218.2 USD
Average target price
216.6 USD
Spread / Average Target
-0.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
RESMED, INC. Stock ResMed, Inc.
+26.82% 31.59B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.62% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.70% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.94% 132B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+24.60% 106B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
-2.66% 62.09B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+4.81% 50.88B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+11.55% 50.8B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-1.09% 40.64B
PHILIPS NV Stock Philips NV
+18.66% 24.39B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. RMD Stock
  4. Financials ResMed, Inc.